bis-PEG4-endo-BCN is a homobifunctional click chemistry linker, PEG increase its aqueous solubility. The BCN group enable copper free click chemitry with azide-tagged molecules. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.
bis-PEG4-endo-BCN is a homobifunctional click chemistry linker, PEG increase its aqueous solubility. The BCN group enable copper free click chemitry with azide-tagged molecules. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.
These DNA polymerases are ideal for Isothermal Amplification
IsoPol® BST+ is a heat-tolerant BST polymerase (large fragment) with enhanced strand-displacement activity. IsoPol® BST+ is active from 25 to 65°C. It is lacking 5’-3’- and 3’-5’-exonuclease activity.
Is the popular choice f or isothermal applications such as LAMP and RT-LAMP at point-of-care diagnostics for its superior amplification performance and robustness. The enzyme is offered in a 1X storage buffer at a concentration < 300 U/µl
(IsoPol® BST+ HC Glycerol FREE) is used to ease the product development processes in sequencing technologies, solid phase amplification and several isothermal technologies. Same performance as IsoPol® BST+ (i.e., high processivity, relative SDA, and relative activity) with the only difference that it is offered in a 2X storage buffer at a concentration > 500 U/
These DNA polymerases are ideal for Isothermal Amplification
IsoPol® BST+ is a heat-tolerant BST polymerase (large fragment) with enhanced strand-displacement activity. IsoPol® BST+ is active from 25 to 65°C. It is lacking 5’-3’- and 3’-5’-exonuclease activity.
| Clone | IHC026 |
| Source | Rabbit Monoclonal |
| Positive Control | Colon Cancer |
| Dilution Range | 1:200 |
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.